TOKYO, Oct 19, 2021 - (JCN Newswire via SEAPRWire.com) - Aichi Cancer Center (1) and Fujitsu Limited today announced the development of an AI solution able to select effective medical treatment from a wide range of drugs based on patients' individual cancer types and various genomic variants (2).Figure1. The newly developed systemThe effectiveness of the new solution has been verified in clinical trials by physicians at Aichi Cancer Center.With current cancer genomic medicine in Japan, treatment plans are considered based on the patients' unique circumstances, including the type of cancer and the actionable genomic variants detected in cancer cells.Specialists for cancer drug treatment thus rely on their own experience, knowledge, and medical literature to study treatment strategies in order to find the best possible medication for the patients' individual conditions.Test data of effective medical treatment of different cancer types and genomic information in external databases, which are sorted and managed based on different keywords and rules, remain difficult to use.Combining the know-how of Aichi Cancer Center in drug selection and Fujitsu's AI-based data-integration technology...